+91 22 24172311
Sections
Search
Subscribe
Equity
Venture Capital
Private Equity
M&A
Mergers & Acquisitions | 16 April 2012

Piramal Healthcare Acquires Bayer AG's Molecular Imaging Portfolio

by Irfan Khan
 
@irfan
@Piramal_Enterprises_L has acquired the molecular imaging development portfolio of Bayer Pharma AG. The terms of the deal were not disclosed, however the deal involves certain milestone and royalty payments.

The acquisition is being made through it's newly created subsidiary - Piramal Imaging SA. The portfolio includes rights to florbetaben, that helps detect beta-Amyloid plaque deposition in the brain – an indication of probable Alzheimer’s disease.

Florbetaben is a radioactive compound being developed by Bayer as an imaging agent for the detection of beta-Amyloid plaque deposition in the brain, which is the pathological hallmark of disease in probable Alzheimer’s disease patients.

IFC May Invest $5Mn In Infuse Capital

IFC may invest upto $5Mn in Infuse Capital - an incubation and early stage fund aimed at seeding and supporting scalable ventures in India through equity investment up to US $1.5Mn per venture.

Read More...

Shubham Housing Secures Investment From Motilal Oswal, Others

Shubham Housing Development Finance Company Private Limited has raised a capital of INR 1,220 Mn from Motilal Oswal Private Equity and its existing investors Helion Venture Partners, Elevar Equity, Accion Frontier and Saama Capital.

Read More...
CONTACT US
Info@DealCurry.com
+91 22 24172311
A 311, 3rd Floor, AntopHill Warehousing Company,
Near Dosti Acres
Wadala(E),
Mumbai 400037
   
 
CLIENTS
USEFUL LINKS
SOLUTIONS
Copyright © EagleEye Research & Media Pvt. Ltd. 2009 All Rights Reserved - Interactive multimedia analysis platform for financial markets.
Site map |Terms of Use |Privacy Policy
DealCurry tracks financial and corporate markets for events, interprets and integrates the information in our platform, providing premium data, news and analytics. DealCurry provides comprehensive coverage of the capital markets through an intuitive, user-friendly interface.